Full-Time
Confirmed live in the last 24 hours
Develops biopharmaceuticals for serious diseases
$108.3k - $176.7k/yr
Senior, Expert
Tarrytown, NY, USA
Regeneron Pharmaceuticals develops medicines aimed at treating serious diseases such as cancer, eye diseases, and allergic conditions. The company uses its own technologies and extensive research to create new therapies, often collaborating with academic institutions and other pharmaceutical companies to enhance its efforts. Unlike many competitors, Regeneron focuses on both research and commercialization, generating revenue through the sale of its approved medicines and strategic partnerships. The goal of Regeneron is to improve patient outcomes by providing effective treatments and ensuring they meet safety and efficacy standards.
Company Size
10,001+
Company Stage
IPO
Headquarters
Town of Greenburgh, New York
Founded
1988
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Wellness Program
Paid Vacation
Equity Awards
Annual Bonuses
Flexible Work Hours
At the American Thoracic Society (ATS) 2025 Congress on 19 May, Sanofi and Regeneron announced the launch of a new Phase IIIb/IV clinical trial, AIM4, during an evening industry symposium.
Purchase is subject to bankruptcy court and regulatory approvals Regeneron will prioritize the privacy, security and ethical use of 23andMe’s customer data; stands ready to work with independent, court-appointed Customer Privacy Ombudsman Planned purchase to strengthen Regeneron’s ongoing
Regeneron acquires 23andMe assets for $256M to expand consumer genomics and data-driven drug discovery.
What You Should Know: – Regeneron Pharmaceuticals, Inc. announced it has been named the successful bidder in the bankruptcy auction for substantially all of the assets of 23andMe Holding Co. – Regeneron plans to acquire 23andMe’s Personal Genome Service® (PGS), Total Health and Research Services business lines, along with its extensive Biobank and associated assets, for $256 million.– Under the terms of the proposed acquisition, Regeneron intends for 23andMe to continue all its consumer genome services uninterrupted. The transaction is subject to bankruptcy court and regulatory approvals, as well as other customary closing conditions, and is anticipated to close in the third quarter of 2025.Strategic Move to Bolster Large-Scale Genetics ResearchRegeneron, a company with a long history of leveraging DNA insights for drug discovery, views this acquisition as a significant step in furthering its research capabilities. Regeneron, a company with a long history of leveraging DNA insights for drug discovery, views this acquisition as a significant step in furthering its research capabilities.“Regeneron was one of the first biotech companies to bet its future on the power of DNA, fueling our drug discovery efforts so as to deliver some of the world’s leading and most innovative medicines,” said George D. Yancopoulos, M.D. Ph.D., co-Founder, Board co-Chair, President and Chief Scientific Officer of Regeneron
Adam Kovalčík, 19, receives $100,000 Top Award for his development of a medicine that can stop viruses from copying genes and controlling infections at the world's largest pre-college STEM competition in Columbus, OhioTARRYTOWN, N.Y. and WASHINGTON, May 16, 2025 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. and Society for Science (the Society) announced that Adam Kovalčík, 19, of Dulovce, Slovakia, won the $100,000 George D. Yancopoulos Innovator Award at the 75th Regeneron International Science and Engineering Fair (Regeneron ISEF), the world's largest pre-college science and engineering competition. The award is named in honor of pioneering drug developer and Regeneron co-Founder, Board co-Chair, President and Chief Scientific Officer. Other top prizes went to projects in sustainable plastics engineering, air quality detection and advancement in prosthetics.Congratulations to the winners of the 2025 Regeneron International Science and Fair!The top winners were recognized during two award ceremonies: the Special Awards on May 15 and the Grand Awards Ceremony on May 16